U.S. markets closed

Insmed Incorporated (INSM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
31.67-3.52 (-10.02%)
At close: 4:00PM EDT

31.50 -0.17 (-0.54%)
After hours: 5:03PM EDT

Insmed Incorporated

700 US Highway 202/206
Bridgewater, NJ 08807-1704
United States
908 977 9900
http://www.insmed.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees435

Key Executives

NameTitlePayExercisedYear Born
Mr. William H. Lewis J.D., M.B.A.Pres, CEO & Chairman1.18M6.28M1969
Mr. Roger AdsettChief Operating Officer728.41kN/A1969
Mr. John Goll IIISr. VP & Chief Accounting Officer482.28k186.54kN/A
Ms. Christine A. Pellizzari J.D.Chief Legal Officer & Corp. Sec.684.6kN/A1968
Ms. S. Nicole SchaefferChief People Strategy Officer612.61k195.32k1968
Ms. Sara M. BonsteinChief Financial OfficerN/AN/A1981
Mr. Walter Perkins Ph.D.Chief Technology OfficerN/AN/AN/A
Mr. John D. Soriano J.D.Chief Compliance OfficerN/AN/A1962
Mandy FaheySr. Director of Corp. CommunicationsN/AN/AN/A
Mr. Drayton WiseSr. VP & Head of United StatesN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Corporate Governance

Insmed Incorporated’s ISS Governance QualityScore as of October 6, 2020 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 9; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.